Imiquimod in dermatology: an overview
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)‐approved for the treatment of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA‐approved indications, off‐label uses, and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sexually Transmitted Diseases Treatment Guidelines, 2006
Skolnik, N. S. (2007) · Current Clinical Practice · doi:10.1007/978-1-59745-313-4_17 · Cited by 3,124
Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells
Rogge, L., Barberis-Maino, L., Biffi, M., Passini, N., Presky, D. H., Gubler, U., & Sinigaglia, F. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.825 · Cited by 766
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
Miller, R. L., Gerster, J. F., Owens, M. L., Slade, H. B., & Tomai, M. A. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00068-x · Cited by 417
Topical treatments for cutaneous warts
Kwok, C. S., Gibbs, S., Bennett, C., Holland, R., & Abbott, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001781.pub3 · Cited by 388
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
Interventions for basal cell carcinoma of the skin
Bath-Hextall, F. J., Perkins, W., Bong, J., & Williams, H. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003412.pub2 · Cited by 357
Marks, R., Gebauer, K., Shumack, S., Amies, M., Bryden, J., Fox, T. L., & Owens, M. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.113689 · Cited by 333
Treatment of genital warts with an immune-response modifier (imiquimod)
Beutner, K. R., Spruance, S. L., Hougham, A. J., Fox, T. L., Owens, M. L., & Douglas, J. M. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70243-9 · Cited by 299
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review
Love, W. E., Bernhard, J. D., & Bordeaux, J. S. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.291 · Cited by 287
Suzuki, H., Wang, B., Shivji, G. M., Toto, P., Amerio, P., Sauder, D. N., Tomai, M. A., & Miller, R. L. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00833.x · Cited by 284
Imiquimod 5% cream in the treatment of Bowen's disease
MacKenzie‐Wood, A. R., Kossard, S., de Launey, J. W., Wilkinson, B., & Owens, M. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.111335 · Cited by 273
Interventions for actinic keratoses
Gupta, A. K., Paquet, M., Villanueva, E., & Brintnell, W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004415.pub2 · Cited by 224
Bath-Hextall, F., Ozolins, M., Armstrong, S. J., Colver, G. B., Perkins, W., Miller, P. S. J., & Williams, H. C. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70530-8 · Cited by 213
Interventions for American cutaneous and mucocutaneous leishmaniasis
González, U., Pinart, M., Rengifo-Pardo, M., Macaya, A., Alvar, J., & Tweed, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004834.pub2 · Cited by 204
Interventions for cutaneous molluscum contagiosum
van der Wouden, J. C., van der Sande, R., Kruithof, E. J., Sollie, A., van Suijlekom-Smit, L. W., & Koning, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004767.pub4 · Cited by 204
Arevalo, I., Ward, B., Miller, R., Meng, T., Najar, E., Alvarez, E., Matlashewski, G., & Llanos‐Cuentas, A. (2001) · Clinical Infectious Diseases · doi:10.1086/324161 · Cited by 189
Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G., & Gilliet, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji207 · Cited by 182
Patel, G. K., Goodwin, R., Chawla, M., Laidler, P., Price, P. E., Finlay, A. Y., & Motley, R. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.01.055 · Cited by 172
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Buates, S., & Matlashewski, G. (1999) · The Journal of Infectious Diseases · doi:10.1086/314782 · Cited by 168
Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
Hadley, G., Derry, S., & Moore, R. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700264 · Cited by 162
Hanke, C. W., Beer, K. R., Stockfleth, E., Wu, J. K., Rosen, T., & Levy, S. F. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.020 · Cited by 155
Megyeri, K., Au, W.-C., ROSZTÓCZY, I., Raj, N. B. K., Miller, R. L., Tomai, M. A., & Pitha, P. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2207 · Cited by 148
Epidermodysplasia Verruciformis: Immunological and Clinical Aspects
Jabłońska, S., & Majewski, S. T. (1994) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-78487-3_9 · Cited by 145
Interventions for cutaneous Bowen's disease
Bath-Hextall, F. J., Matin, R., Wilkinson, D., & Leonardi‐Bee, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007281.pub2 · Cited by 131
Ruocco, E., Ruocco, V., Tornesello, M. L., Gambardella, A., Wolf, R., & Buonaguro, L. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2013.01.008 · Cited by 129
Miranda‐Verástegui, C., Llanos‐Cuentas, A., Arevalo, I., Ward, B. J., & Matlashewski, G. (2005) · Clinical Infectious Diseases · doi:10.1086/429238 · Cited by 129
Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism
Patel, U., Mark, N. M., Machler, B. C., et al. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10124.x · Cited by 116
Arevalo, I., Tulliano, G., Quispe, A., Späth, G. F., Matlashewski, G., Llanos‐Cuentas, A., & Pollack, H. J. (2007) · Clinical Infectious Diseases · doi:10.1086/518172 · Cited by 116
Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression.
Kono, T., Kondo, S., Pastore, S., Shivji, G. M., Tomai, M. A., McKenzie, R. C., & Sauder, D. N. (1994) · PubMed · Cited by 113
Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
Wolf, I. H., Cerroni, L., Kodama, K., & Kerl, H. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.4.510 · Cited by 106
Keratoacanthoma: a tumor in search of a classification
Karaa, A., & Khachemoune, A. (2007) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2007.03260.x · Cited by 103
Suchin, K. R. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.9.1137 · Cited by 96
Current issues in the management of actinic keratosis.
Ceilley, R., & Jorizzo, J. (2013) · Journal of American Academy of Dermatology · doi:10.1016/j.jaad.2012.09.051 · Cited by 96
Aspord, C., Tramcourt, L., Leloup, C., Molens, J., Leccia, M. ‐., Charles, J., & Plumas, J. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.194 · Cited by 86
Harrison, L., Skinner, S. L., Marbury, T., Owens, M., Kurup, S., McKane, S. W., & Greene, R. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0465-4 · Cited by 85
Imiquimod as an antiangiogenic agent.
Li, V. W., Li, W. W., Talcott, K. E., & Zhai, A. W. (2005) · PubMed · Cited by 85
Efficacy of S26308 against guinea pig cytomegalovirus infection
Chen, M., Griffith, B. P., Lucia, H. L., & Hsiung, G. D. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.678 · Cited by 84
Interventions for cutaneous molluscum contagiosum
van der Wouden, J. C., van der Sande, R., van Suijlekom‐Smit, L. W., Berger, M. Y., Butler, C., & Koning, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004767.pub3 · Cited by 80
Treatment of Squamous Cell Carcinoma In Situ: A Review
Shimizu, I., Cruz, A. P., Chang, K. H., & Dufresne, R. G. (2011) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2011.02088.x · Cited by 75
McCuaig, C. C., Dubois, J., Powell, J., Belleville, C., David, M., Rousseau, É., Gendron, R., Jafarian, F., & Auger, I. (2009) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2008.00857.x · Cited by 75
Efficacy of Imiquimod 5% Cream in the Treatment of Recalcitrant Warts in Children
Grußendorf-Conen, E.-I., & Jacobs, S. (2002) · Pediatric Dermatology · doi:10.1046/j.1525-1470.2002.00083.x · Cited by 74
Turza, K. C., Dengel, L. T., Harris, R. C., Patterson, J. W., White, K., Grosh, W. W., & Slingluff, C. L. (2009) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2009.01290.x · Cited by 69
Berthelot, C., Dickerson, M. C., Rady, P. L., He, Q., Niroomand, F., Tyring, S. K., & Pandya, A. G. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.01.036 · Cited by 68
Schacker, T. W., Conant, M. A., Thoming, C., Stanczak, T. L., Wang, Z., & Smith, M. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3243-3248.2002 · Cited by 61
Berman, B., Harrison-Balestra, C., Perez, O. A., Viera, M. H., Villa, A. M., Zell, D. S., & Ramirez, C. C. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.10.064 · Cited by 58
Stockfleth, E., Ulrich, C., Hauschild, A., Lischner, S., Meyer, T., & Christophers, E. (2002) · PubMed · Cited by 56
Nichols, D. B., & Shisler, J. L. (2005) · Journal of Virology · doi:10.1128/jvi.80.2.578-586.2006 · Cited by 52
Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer
Papadavid, E., Stratigos, A., & Falagas, M. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1743 · Cited by 48
Imiquimod applied topically: A novel immune response modifier.
Tyring, S. K. (2001) · PubMed · Cited by 44
Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study
Bernstein, D. I., Spruance, S. L., Arora, S. S., Schroeder, J., & Meng, T. C. (2005) · Clinical Infectious Diseases · doi:10.1086/432802 · Cited by 43
Kan, Y., Okabayashi, T., Yokota, S., Yamamoto, S., Fujii, N., & Yamashita, T. (2012) · Journal of Virology · doi:10.1128/jvi.01196-12 · Cited by 40
Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman, D. K., & Carroll, M. T. (2007) · PubMed · Cited by 40
The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids.
Chuangsuwanich, A., & Gunjittisomram, S. (2007) · PubMed · Cited by 39
Lascaux, A., Caumes, É., Deback, C., et al. (2011) · Journal of Medical Virology · doi:10.1002/jmv.23188 · Cited by 35
Vavricka, B. M. P., Hofbauer, G. F. L., Dummer, R., French, L. E., & Kempf, W. (2012) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2011.04278.x · Cited by 30
Lupus Erythematosus–Like Reaction in Imiquimod-Treated Skin: A Report of 2 Cases
Chan, M. P., & Zimarowski, M. J. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181f2bf9e · Cited by 29
Qiu, Y., Ma, G., Lin, X., Jin, Y., Chen, H., & Hu, X. (2012) · Pediatric Dermatology · doi:10.1111/pde.12002 · Cited by 21
Kulp, J., Levy, S. F., Fein, M., et al. (2010) · Archives of Dermatological Research · doi:10.1007/s00403-010-1041-8 · Cited by 17
Lmax and imiquimod 3.75%: the new standard in AK management
Stockfleth, E. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12824 · Cited by 16
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod
Stavrakoglou, A., Brown, V. L., & Coutts, I. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07976.x · Cited by 15
Cytokine Dermatitis and Febrile Seizure From Imiquimod
Mosher, J. S., & Lio, P. (2012) · PEDIATRICS · doi:10.1542/peds.2011-0936 · Cited by 13
Gupta, G., Stockfleth, E., Peris, K., Aractingi, S., Alomar, A., Dakovic, R., & Dirschka, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12697 · Cited by 11
Ogawa, Y., Kawamura, T., Matsuzawa, T., Aoki, R., & Shimada, S. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.07.004 · Cited by 10
Microinvasive Melanoma: Cutaneous Pharmacotherapeutic Approaches
Quigley, E. A., & Halpern, A. C. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0012-1 · Cited by 8
Cited by
Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics
Xu, C., Huang, J., Jiang, Y., He, S., Zhang, C., & Pu, K. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00978-z · Cited by 267
Cosmetic and Therapeutic Applications of Fish Oil’s Fatty Acids on the Skin
Huang, T.-H., Wang, P.-W., Yang, S.-C., Chou, W.-L., & Fang, J.-Y. (2018) · Marine Drugs · doi:10.3390/md16080256 · Cited by 210
“Imiquimod is a toll-like receptor 7/8 agonist prescribed as a topical drug for treating actinic keratosis, skin warts, and malignancy [69].”
BackgroundPharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Sunlight, Vitamin D, and Xeroderma Pigmentosum
Martens, M. C., Emmert, S., & Boeckmann, L. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-46227-7_16 · Cited by 24
Metadata
- Authors
- Hanna, E., Abadi, R., & Abbas, O.
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2016-07-08
- Volume
- 55
- Issue
- 8
- Pages
- 831-844
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W2468627168
- Cited by
- 215
- References
- 67
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.